VIVUS Inc. (VVUS)

4.10
NASDAQ : Health Technology
Prev Close 4.16
Day Low/High 3.98 / 4.20
52 Wk Low/High 2.15 / 5.78
Avg Volume 108.20K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 44.27M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Parsing a Pair of Reports

Two model portfolio names announced first-quarter earnings results overnight. Here's our take on each.

A Pair of Previews

Here's what we'll be listening for when these two model portfolio names discuss earnings later today and tomorrow.

Get Ready for a Monday Rally

The first trading day of the month often has a seasonal upswing, but the market will likely decline again later in the week.

Stocks Under $10 Weekly Summary

Three model portfolio names reported earnings results this week as the broad market took a slide.

Stocks Under $10 Weekly Summary

This week, we added one name to the model portfolio and locked in a strong profit by closing out another position.

Stocks Under $10 Weekly Summary

This week, we added to one model portfolio position and took some profits in two others.

Good News for a Biotech Name

An investment firm has initiated coverage with a buy rating on this model portfolio stock.

Stocks Under $10 Weekly Summary

The model portfolio gained a new name this week as it followed the upward trend of financial and retail stocks.

14 Biotech Stocks Facing FDA Approval

News of a drug's approval or rejection from the FDA can rock or kill a biotech stock's price. Here are 14 companies with drugs facing FDA approval decisions in 2010.

Stocks Under $10 Weekly Summary

A new name joined the model portfolio as the second quarter kicked off during this holiday-shortened week.

Stocks Under $10 Weekly Summary

During an intriguing week for the markets, we focused on compiling a list of potential new names to add to the model portfolio.

Shares Riding High

This model portfolio position is trading higher amid rumors regarding a potential partnership for its obesity drug.

Stocks Under $10 Weekly Summary

This week, we padded our position in one model portfolio name and took some profits in another.

Stocks Under $10 Weekly Summary

We made some sales in the model portfolio this week, as the major market averages hit their highest levels in over a year.

Outlook Seems Healthy

This model portfolio biotech name reported fourth-quarter results that exceeded the consensus analyst estimates.

Earnings Preview

Though there is plenty of risk in the model, we believe the potential reward makes this stock attractively valued.

Stocks Under $10 Weekly Summary

It was a volatile week for the model portfolio, as we navigated through a lot of earnings reports.

Good News Boosts Shares

This model portfolio name is trading higher this morning on word that the FDA accepted its obesity drug application.

Stocks Under $10 Weekly Summary

A busy week of positive earnings reports for the model portfolio names left us with an upbeat outlook for 2010.

Stocks Under $10 Weekly Summary

Solid earnings results boosted the model portfolio this week, and we have more reports to look forward to next week.

Stocks Under $10 Weekly Summary

Despite the volatile trading activity this week, we added shares to only one position in the model portfolio.

Stocks Under $10 Weekly Summary

The market's volatility made for an extremely busy week for the model portfolio as we made adjustments to several holdings.

Adding to a Holding

Taking advantage of the leg down in the broader market, we're upping our shares in this name.

Stocks Under $10 Weekly Summary

A new stock joined the model portfolio this week and we used the increased volatility to build up two other names.

Stocks Under $10 Weekly Summary

We used the volatility in the market this week to make several trades and add a new model portfolio position.

Buying and Selling

Using today's selloff to close out a Three-rated holding to fund additions to two of our other model portfolio names.

Stocks Under $10 Weekly Summary

As earnings season began this week, we focused on researching some potential new names for the model portfolio.

Positive Test Results Lift Shares

This name is trading higher today after reporting strong phase III trial data for one its promising new drugs.

Biotech News on Cusp of J.P. Morgan Confab: BioBuzz

Biotech News on Cusp of J.P. Morgan Confab: BioBuzz

The J.P. Morgan Healthcare Conference kicks off with a flurry of biotech company updates.

Stocks Under $10 Weekly Summary

The major averages kicked off 2010 on a positive note and a new stock joined the model portfolio this week.

TheStreet Quant Rating: D (Sell)